Fig. 4From: High inter-laboratory variability in the assessment of HER2-low breast cancer: a national registry study on 50,714 Danish patientsAssays and staining platforms for HER2 immunohistochemistry (data kindly provided by NordiQC). (CDx, Companion diagnostics; LDT, Laboratory developed test)Back to article page